ArticlePLoS pathogens2025
A lignan compound regulates LPS modifications via PmrA/B signaling cascades to potentiate colistin efficacy in vivo.
Article in PLoS pathogens, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Natural molecule potentiates colistin efficacyVirulence · 2026Article
- Time-resolved proteomic adaptation of multidrug-resistantMicrobiology spectrum · 2026Article
- Spread potential and architectural variant of a multiple-drug resistantFrontiers in microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
There has been a substantial gap between drying antibiotic pipeline and ongoing antibiotic resistance crisis, necessitating approaches to revitalize existing antimicrobials to meet unmet clinical demand for viable treatments. Herein, a lignan compound, magnolol, was identified that profoundly potentiates colistin (CS) to eradicate Gram negative bacteria and curb the development of resistance under host-mimicking condition. The mechanistic study showed that magnolol is able to disrupt PmrA/B two component signaling by dissociating the PmrA regulator protein from its cognate DNA including eptA and arnT. This action blocks the PmrA/B-dependent protective modifications of lipopolysaccharide (LPS) to reduce the net charges of bacterial membrane, thereaby facilitating its electrostatic interaction with CS. MAG-facilitated enhancement of CS binding promotes the formation of toroidal pores in the bacterial membrane, which in turn triggers rapid bacterial death by inducing lethal cytoplasmic contents leakage. In sum, this work not only illustrates the great potential of untapped phytoconstitutes such as magnolol in confronting antibiotic resistance but also reveals that silencing PmrA/B signaling as a favorable strategy to potentiate CS activity in vivo.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.